Long-term avelumab in advanced non-small-cell lung cancer: Summaries and post hoc analyses from JAVELIN Solid Tumor

Borys Hrinczenko, Nicholas Iannotti, Sanjay Goel, David Spigel, Howard Safran, Matthew H. Taylor, Jaafar Bennouna, Deborah J. Wong, Karen Kelly, Claire Verschraegen, Marcis Bajars, Juliane Manitz, Mary Ruisi, James L. Gulley

Research output: Contribution to journalArticlepeer-review

Abstract

Background: This study examined patients with advanced non-small-cell lung cancer who received long-term avelumab (anti-PD-L1) in a large phase Ib trial (JAVELIN Solid Tumor). Methods: Patients receiving >2 years of avelumab were reviewed and exploratory descriptive analyses were conducted. Results: Individuals with varying baseline characteristics who had received up to 6 years of avelumab were reviewed. Overall, 37/340 (10.9%) had received ≥2 years of treatment; in this subgroup, best response was complete response in 5.4%, partial response in 59.5% and stable disease in 29.7%; 51.4% had continued treatment beyond disease progression. Conclusions: In this study, 11% of patients with advanced non-small-cell lung cancer received ≥2 years of avelumab treatment and experienced prolonged response or continued clinical benefit.

Original languageEnglish (US)
Pages (from-to)1333-1342
Number of pages10
JournalFuture Oncology
Volume18
Issue number11
DOIs
StatePublished - Apr 2022

Keywords

  • Clinical trials
  • Immunotherapy
  • Lung
  • Metastasis
  • Solid tumors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Long-term avelumab in advanced non-small-cell lung cancer: Summaries and post hoc analyses from JAVELIN Solid Tumor'. Together they form a unique fingerprint.

Cite this